Zacks Research Has Bearish Forecast for Qiagen Q1 Earnings

Qiagen N.V. (NYSE:QGEN) – Analysts at Zacks Research cut their Q1 2026 earnings per share estimates for shares of Qiagen in a research note issued on Wednesday, February 25th. Zacks Research analyst Team now anticipates that the company will earn $0.56 per share for the quarter, down from their previous estimate of $0.61. The consensus estimate for Qiagen’s current full-year earnings is $2.26 per share. Zacks Research also issued estimates for Qiagen’s Q2 2026 earnings at $0.63 EPS, Q3 2026 earnings at $0.65 EPS, FY2026 earnings at $2.51 EPS, Q2 2027 earnings at $0.68 EPS, Q3 2027 earnings at $0.69 EPS, FY2027 earnings at $2.81 EPS and FY2028 earnings at $3.02 EPS.

Qiagen (NYSE:QGEN) last released its quarterly earnings results on Thursday, February 5th. The company reported $0.62 earnings per share for the quarter, beating the consensus estimate of $0.61 by $0.01. The company had revenue of $540.42 million for the quarter, compared to analyst estimates of $528.53 million. Qiagen had a return on equity of 14.56% and a net margin of 20.33%.The firm’s revenue was up 3.6% on a year-over-year basis. During the same period in the previous year, the company posted $0.61 earnings per share.

Other research analysts have also issued reports about the stock. Jefferies Financial Group reiterated a “buy” rating and issued a $59.00 price target on shares of Qiagen in a research note on Thursday, February 5th. JPMorgan Chase & Co. upped their price objective on shares of Qiagen from $55.00 to $60.00 and gave the stock an “overweight” rating in a report on Friday, February 6th. UBS Group set a $52.00 target price on shares of Qiagen in a research note on Monday, February 9th. Stifel Nicolaus set a $50.00 target price on shares of Qiagen and gave the company a “hold” rating in a report on Friday, February 6th. Finally, Robert W. Baird set a $53.00 price target on Qiagen in a research report on Friday, February 6th. Four investment analysts have rated the stock with a Buy rating and eight have given a Hold rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $55.20.

Qiagen Stock Performance

Shares of Qiagen stock opened at $49.07 on Friday. Qiagen has a 12 month low of $39.61 and a 12 month high of $57.81. The firm has a market capitalization of $10.36 billion, a P/E ratio of 24.34, a P/E/G ratio of 2.37 and a beta of 0.67. The company has a current ratio of 3.90, a quick ratio of 3.31 and a debt-to-equity ratio of 0.44. The business has a fifty day simple moving average of $49.97 and a two-hundred day simple moving average of $49.38.

Institutional Investors Weigh In On Qiagen

Several institutional investors and hedge funds have recently made changes to their positions in QGEN. Lingohr Asset Management GmbH purchased a new position in shares of Qiagen in the 3rd quarter worth $4,218,000. Gateway Investment Advisers LLC purchased a new stake in Qiagen during the third quarter valued at $1,197,000. SG Americas Securities LLC bought a new position in Qiagen in the third quarter valued at about $1,032,000. Great Lakes Advisors LLC purchased a new position in Qiagen in the third quarter worth about $3,677,000. Finally, Generali Asset Management SPA SGR boosted its position in Qiagen by 102.8% in the third quarter. Generali Asset Management SPA SGR now owns 68,880 shares of the company’s stock worth $3,078,000 after purchasing an additional 34,912 shares during the last quarter. Institutional investors own 70.00% of the company’s stock.

Qiagen Company Profile

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.